Exploratory Study of a Digital Therapeutics in People With Schizophrenia

Completed · Not applicable

Conditions studied: Schizophrenia

In brief

CT-155 is a novel prescription digital therapeutic (PDT) being developed by Click Therapeutics, Inc. (Click) and Boehringer Ingelheim (BI) using an interactive, software-based intervention to treat schizophrenia

Key facts

Study ID: NCT05438160
Run by: Click Therapeutics, Inc.
People needed: 48
Starts: 2022-03-31
Expected to finish: 2022-07-31
Last updated by the study team: 2025-07-17

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

1. Is willing and able to provide written informed consent to participate in the study, attend study visits, and comply with study-related requirements and assessments.
2. Between 18 and 64 years of age at time of informed consent.
3. Fluent in written and spoken English, confirmed by ability to read and understand the informed consent form.
4. Has a primary diagnosis of schizophrenia using the diagnostic criteria for schizophrenia as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), for at least 1-year prior to screening.
5. Is in the stable phase of illness, as assessed by the investigator after review of medical records or documented discussion with the treating physician.
6. Has outpatient treatment status at the time of screening, with no inpatient treatment for schizophrenia within 12 weeks prior to screening.
7. Is on a stable dose of antipsychotic medication(s) for at least 12 weeks prior to enrollment (Day 1) as determined by the investigator.
8. Has obtained a score of 30 or less on the MAP-SR as assessed at the screening visit.
9. Is the sole user, per participant self-report, of an iPhone with an iPhone operating system (iOS) 13 or greater or a smartphone with an Android operating system 9 or greater and is willing to download and use the Study App as required per the protocol.
10. Is the owner of, and has regular access to, an email address.
11. Has regular access to the internet via cellular data plan and/or wifi.
12. Has stable housing and has remained at the same residence for at least 12 weeks prior to screening, with no anticipated housing changes during the duration of the study.
13. Understands how to use the Study App during the screening visit as assessed by the investigator during in-clinic Study App installation and activation activities.

You may not qualify if…

1. Is currently treated with more than two antipsychotic medications (including more than two dosage forms).
2. Is currently treated with clozapine or haloperidol.
3. Has active prominent positive symptoms in the opinion of the investigator that would preclude effective engagement in treatment for negative symptoms.
4. Is currently receiving or has received psychotherapy within 12 weeks prior to screening.
5. Meets either the International Classification of Diseases, Tenth Revision (ICD-10) or DSM-5 criteria for diagnoses not under investigation, including schizophreniform, schizoaffective, or psychosis non-specific disorders.
6. Has post-traumatic stress disorder (PTSD), bipolar disorder, major depressive disorder, developmental disorders, or any prominent disorder that would interfere with compliance to the protocol, per investigator judgment.
7. Has substance or alcohol use disorder (excluding caffeine and nicotine), that would interfere with compliance to the protocol, per investigator judgment.
8. Currently needs or will likely require prohibited concomitant medications and/or therapy during the study, as determined by the investigator.
9. Is currently participating in another clinical study (interventional or observational) involving investigational drugs or devices.
10. Prior participation in the CT-155-C-001 clinical study.
11. Has suicidal ideation or behavior, as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS):
Participants with a "yes" response to either Items 4 or 5 on the C-SSRS Suicidal Ideation Item within the last 12 weeks prior to screening or at baseline visit.
Participants with a "yes" response on the C-SSRS Suicidal Behavior Items within the last 26 weeks prior to screening or at baseline visit.
Participants who, in the opinion of the investigator, present a serious risk of suicide.
12. In the judgment of the investigator, any evidence of a clinically significant concomitant disease or any other clinical condition that would jeopardize the participant's safety while participating in the clinical study.

Where it is running

CT-155 Center — Anaheim, California, United States
CT-155 Center — Torrance, California, United States
CT-155 Center — Hialeah, Florida, United States
CT-155 Center — Lake Mary, Florida, United States
CT-155 Center — Miami, Florida, United States
CT-155 Center — Irving, Texas, United States
CT-155 Center — Richmond, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.